Results 101 to 110 of about 123,506 (328)

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis &Rheumatology, Accepted Article.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify non‐invasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin, Leonardo Palazzo, Agnes B. Fogo, Mark Haas, David R. W. Jayne, Liz Lightstone, Brad H. Rovin, Surya V. Seshan, Augusto Vaglio, Ioannis Parodis, Ingeborg M. Bajema, The LN classification steering committee   +11 more
wiley   +1 more source

A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. [PDF]

PLoS ONE, 2014
Although albuminuria and subsequent advanced stage chronic kidney disease are common among patients with diabetes, the rate of increase in albuminuria varies among patients.
Dov Shiffman, Guillaume Pare, Rainer Oberbauer, Judy Z Louie, Charles M Rowland, James J Devlin, Johannes F Mann, Matthew J McQueen   +7 more
doaj   +1 more source

Urinary Tubular Injury Biomarkers Are Associated With ESRD and Death in the REGARDS Study. [PDF]

, 2018
IntroductionUrinary neutrophil gelatinase-associated lipocalin (uNGAL) and urinary kidney injury molecule-1 (uKIM-1) are established markers of subclinical acute kidney injury.
Bennett, Michael, Cushman, Mary, Dubin, Ruth F, Judd, Suzanne, Parikh, Chirag, Peralta, Carmen A, Powe, Neil, Sarnak, Mark, Scherzer, Rebecca, Shlipak, Michael, Warnock, David G   +10 more
core  

A discrete cluster of urinary biomarkers discriminates between active systemic lupus erythematosus patients with and without glomerulonephritis. [PDF]

, 2016
BackgroundManagement of lupus nephritis (LN) would be greatly aided by the discovery of biomarkers that accurately reflect changes in disease activity.
Avila-Casado, Carmen, Bonilla, Dennisse, Boutros, Paul C, Fortin, Paul R, Landolt-Marticorena, Carolina, Morrison, Stacey, Noamani, Babak, Prokopec, Stephenie D, Reich, Heather, Scholey, James, Wither, Joan   +10 more
core   +3 more sources

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Effect of Albuminuria on the State of Plasma Hemostasis in Patients with Essential Hypertension

Počki, 2016
In recent decades, numerous scientific works are devoted to the study of the clinical and prognostic significance of albuminuria, methods of its detection, as well as treatment measures aimed at controlling this pathological condition.
A.I. Pastushyna, O.M. Plenova
doaj   +1 more source

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Cancer Communications, EarlyView.
Abstract Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 (KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).
Jian Li, Ting Deng, Yanhong Gu, Antonio Calles Blanco, Zhihua Li, Chunmei Bai, Lin Wu, Jing Huang, Xingya Li, Yu Yao, Zhengbo Song, Yongsheng Li, Lian Liu, Ligang Xing, Wenming Wu, Julia Martínez‐Pérez, Ayala Hubert, Jon Zugazagoitia, Jian Zhang, Yongsheng Wang, Yanqiu Zhao, Guilan Wen, Guohao Xia, Diansheng Zhong, Xueqin Chen, Kuirong Jiang, Andrea Wang‐Gillam, Yuli Ding, Sumei Liu, Zhiyue Rao, Xinghu Liu, Lin Shen   +31 more
wiley   +1 more source

Correlation Between HbA1c and Albuminuria in Type 2 Diabetes Mellitus

Majalah Kedokteran Bandung, 2020
In patients with type 2 diabetes mellitus (Type 2 DM), glycemic control plays an essential role in reducing macro- and microvascular complications. The earliest marker for diabetic nephropathy is the presence of albuminuria.
Jesika Merlin, Pusparini Pusparini
doaj   +1 more source

Elevated hemoglobin glycation index identify non-diabetic individuals at increased risk of kidney dysfunction [PDF]

, 2017
Hemoglobin glycation index (HGI), calculated as the difference between the observed value of HbA1 and the predicted HbA1c based on plasma glucose concentration, is a measure of the individual tendency toward non-enzymatic hemoglobin glycation which has ...
Andreozzi, F, Fiorentino, Tv, Marini, Ma, Perticone, F, Sciacqua, A, Sesti, G, Succurro, E   +6 more
core   +2 more sources